Spectinomycin + Lincomycin Combination: Synergy Guide for Enteric & Respiratory Infections

The fixed-dose combination of spectinomycin + lincomycin — known commercially as Lincospectin (brands: 禽利高, 易力能) — is one of the most widely prescribed veterinary antimicrobial combinations for poultry respiratory and enteric disease. The rationale is straightforward: no single antimicrobial covers all the relevant pathogens; together, spectinomycin and lincomycin provide comprehensive coverage.

Synergy Mechanism: Complementary Spectra

The spectinomycin + lincomycin combination does not rely on pharmacological synergy in the strict sense (one drug increasing the other's potency). Rather, it is a rational pairing based on complementary antibacterial spectra that together eliminate the full range of clinically relevant pathogens in poultry respiratory and enteric disease:

Spectinomycin Covers	Lincomycin Covers
Gram-negative bacteria: E. coli, Salmonella spp., Pasteurella multocida, Haemophilus spp.	Gram-positive bacteria: Staphylococcus spp., Streptococcus spp., Clostridium perfringens
Mycoplasma: M. gallisepticum, M. synoviae	Obligate anaerobes: Clostridium spp., Fusobacterium necrophorum
Together: Complete coverage of the major bacterial and mycoplasmal pathogens encountered in poultry and swine respiratory and enteric disease complexes.

This complementary relationship addresses a critical clinical need: in poultry disease, mixed infections with Gram-negative bacteria, Gram-positive organisms, Mycoplasma, and anaerobes are the rule, not the exception. CRD, for example, typically involves M. gallisepticum plus E. coli (covered by spectinomycin) with secondary Gram-positive involvement (covered by lincomycin). Necrotic enteritis in poultry, caused by Clostridium perfringens, is an anaerobic infection that lincomycin addresses effectively while spectinomycin handles concomitant enteric coliforms.

Standard Formulations

100g Soluble Powder

The standard veterinary Lincospectin formulation is a 100g water-soluble powder containing:

• Spectinomycin hydrochloride: 40g active
• Lincomycin hydrochloride: 20g active
• Excipients to 100g (typically lactose or dextrose carrier with pH stabilizers)

This 2:1 ratio reflects the clinical evidence: spectinomycin provides the broader Gram-negative and Mycoplasma component, while lincomycin at a lower proportion supplies Gram-positive and anaerobic coverage. The pH of the reconstituted solution should be maintained between 5.5 and 7.0 for optimal stability of both components.

Injectable Formulations

Injectable Lincospectin products are available for day-old chick administration and, in some markets, for swine. These are typically supplied as sterile solutions in multi-dose vials for hatchery or veterinary use.

Dosing Routes and Protocols

Route	Species	Dosage	Duration
Drinking water	Poultry	0.5–0.8 g/L (as total powder)	3–5 days
Feed	Poultry, swine	250–500 g/ton feed	5–7 days
Injection (day-old chicks)	Poultry	1 vial per 2,000–3,000 chicks	Single dose

Drinking Water Considerations

Medicated water should be prepared fresh every 24 hours. Both spectinomycin and lincomycin are stable in aqueous solution at pH 5.5–7.0 and at ambient temperatures up to 25 degrees Celsius for this period. Water lines must be flushed before and after medication. During treatment, medicated water should be the sole source of drinking water.

Feed Administration

Feed-grade Lincospectin premix is incorporated at 250–500 g per ton of finished feed. Homogeneity of mixing must be verified, as uneven distribution leads to under-dosing in some animals and potential residue violations in others. The 250 g/ton rate is used for prevention during known disease risk periods; 500 g/ton for treatment of active clinical disease.

Clinical Indications

Species	Indication	Key Pathogens
Broilers	Chronic Respiratory Disease (CRD)	M. gallisepticum + E. coli
Broilers	Necrotic enteritis	Clostridium perfringens + E. coli
Layers/Breeders	Infectious coryza + CRD	Avibacterium paragallinarum + M. gallisepticum
Swine	Post-weaning enteritis	E. coli + Clostridium spp.
Swine	Swine dysentery	Brachyspira hyodysenteriae

Safety and Withdrawal Period

The combination has a well-established safety profile. Adverse effects are uncommon at recommended doses. Transient soft feces have been reported in a small proportion of treated animals, resolving upon completion of therapy. The primary safety consideration is the withdrawal period:

• Poultry (meat): 5 days
• Swine (meat): 5 days
• Laying hens: Not authorized for birds producing eggs for human consumption

These withdrawal periods should be verified against the specific product registration in the target market, as regulatory requirements vary by country. For the individual API products that go into Lincospectin formulations, see the spectinomycin HCl product page and lincomycin HCl product page for specifications, documentation packages, and supply information.